The Beatrice Hunter Cancer Research Institute logo
  • Dr. Zhaolin Xu, MD, FRCPC, FCAP

Appointments:

Professor, Department of Pathology, Faculty of Medicine, Dalhousie University 

Pulmonary Pathologist and Cytopathologist, QE II Health Sciences Centre, NSHA

Chair, Pathology Working Group and Network Member, Pan-Canadian Lung Cancer Screening Network, Canadian Partnership Against Cancer (CPAC)

Chair, Pathology Working Group and Steering Committee Member, Lung Cancer Screening Network, Cancer Care Nova Scotia (CCNS) 

Committee Member, Correlative Sciences and Tumor Biology Committee, and Lung Tumor Sub-committee, Candian Clinical Trial Group (CCTG) 

Expert Panel Member, Lung National Cancer Pathology and Staging Multidisciplinary Expert Panel, Canadian Partnership Against Cancer (CPAC)

Board of Directors and Medical Advisory Committee Member, Lung Cancer Canada (LCC) 

Cancer Protocol Review Penal, Lung and Mediastinal Tumors, and Gynecologic Tumors, College of American Pathologists

Affiliations:

Dalhousie University, Faculty of Medicine Queen Elizabeth II Health Sciences Centre, Capital Health

Research Interests:

Lung cancer genotyping and molecular profiling, Lung tumor banking, Metastasis and early detection of lung cancer

Molecular classification of lung cancer is essential in modern oncology

Molecular classification of lung cancer based on gene mutational status has a significant impact on patient’s clinical management that is considered as one of the new directions in modern oncology. Dr. Zhaolin Xu is studying gene mutations in human lung cancer in addition to pathological assessment of the tumor. Lung cancer patients can be divided into various subgroups based on not only tumor morphology but also molecular profiling, and selected to receive personalized targeted therapy accordingly. Dr. Xu and his colleagues have established the QE II Lung Tumor Bank for research since 2005, which is certified by the Canadian Tumor Repository Network (CTRNet). Dr. Xu is the Director of the tumor bank which has become one of the largest human lung tumor banks in the country. Dr. Xu’s research interest also includes lung cancer metastasis and early detection, and immune checkpoints in lung cancer.

Involvement with BHCRI to date:

Dr. Xu is a BHCRI Senior Scientist and has been a BHCRI Seminar Series presenter.

Phone:

902-473-7287

Contact:

Mackenzie Building, 5788 University Ave., Halifax NS B3H 1V8
Site by: Spectacle Group